Search research articles
Contact Us
Filters
Showing results (241-250 of 266) with videos related to
Page
of 27
Sort By:
Cancer Cell
|
October 21, 2015
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis
Robert W Schnepp, Priya Khurana, Edward F Attiyeh, et al.
Oncotarget
|
September 9, 2017
Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126
Anat Erdreich-Epstein, Alok R Singh, Shweta Joshi, et al.
Cancer
|
August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group
Larry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
The New England Journal of Medicine
|
October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma
David L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Cancer
|
July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group
J D Frost, J A Hank, G H Reaman, et al.
British Journal of Cancer
|
June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
L L Wang, R Teshiba, N Ikegaki, et al.
Cancer Research
|
October 12, 2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy
David C Delgado, Jacquelyn A Hank, Jill Kolesar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2008
Molecular characterization of the pediatric preclinical testing panel
Geoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Journal of the National Cancer Institute
|
May 15, 2015
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy
Kishore B Challagundla, Petra M Wise, Paolo Neviani, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 266) with videos related to
Sort By:
Page
of 27
Cancer Cell
|
October 21, 2015
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis
Robert W Schnepp, Priya Khurana, Edward F Attiyeh, et al.
Oncotarget
|
September 9, 2017
Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126
Anat Erdreich-Epstein, Alok R Singh, Shweta Joshi, et al.
Cancer
|
August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group
Larry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
The New England Journal of Medicine
|
October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma
David L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Cancer
|
July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group
J D Frost, J A Hank, G H Reaman, et al.
British Journal of Cancer
|
June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
L L Wang, R Teshiba, N Ikegaki, et al.
Cancer Research
|
October 12, 2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy
David C Delgado, Jacquelyn A Hank, Jill Kolesar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2008
Molecular characterization of the pediatric preclinical testing panel
Geoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Journal of the National Cancer Institute
|
May 15, 2015
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy
Kishore B Challagundla, Petra M Wise, Paolo Neviani, et al.
Page
of 27